X4 Pharmaceuticals

X4 Pharmaceuticals is a biopharmaceutical company headquartered in Boston, Massachusetts, and publicly traded on the Nasdaq Global Market under the symbol XFOR. According to its own materials, X4 develops and commercializes innovative therapies for patients with rare diseases of the immune system and significant unmet needs. The company states that it has successfully developed mavorixafor, receiving U.S. approval for XOLREMDI (mavorixafor) in its first indication, and that it is advancing mavorixafor for additional patient populations while enrolling participants in a pivotal, global Phase 3 clinical trial (the 4WARD trial) in people with certain chronic neutropenic disorders.

X4 Pharmaceuticals describes itself as delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. The company states that it has successfully developed mavorixafor, receiving U.S. approval for XOLREMDI (mavorixafor) in its first indication, and that it is currently advancing mavorixafor for additional patient populations while enrolling participants in a pivotal, global Phase 3 clinical trial (the 4WARD trial) in people with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts, and is publicly traded on the Nasdaq Global Market under the symbol XFOR.

Developing and commercializing innovative therapies for patients with rare diseases of the immune system and significant unmet needs.

• XOLREMDI (mavorixafor)

• mavorixafor

1. 1Home - X4 Pharmaceuticalsx4pharma.com
2. 2About - X4 Pharmaceuticalsx4pharma.com
3. 3X4 Pharmaceuticals Appoints William E. Aliski to Board of Directorsbiospace.com